食管癌患者外周血基因表达谱研究

目的用基因芯片技术研究食管癌患者外周血和正常人基因表达谱差异,筛选与食管早期癌变相关的基因。方法分别抽提食管癌患者外周血细胞和正常人外周血细胞总RNA并纯化mRNA;将各mRNA逆转录合成以Cy5和Cy3标记的cDNA一链做探针,混合后在1张含有4096条双点人类全长基因的芯片上进行杂交。用扫描仪扫描芯片荧光信号图像,用软件对扫描图象进行数字化处理和分析。结果食管癌患者外周血细胞和正常人外周血比较差异2倍以上的共有92个基因。其中差异3倍以上共有36个基因。有2个人尿激酶型纤溶酶原激活物受体(uPAR)基因显著上调,80K—L蛋白基因、蛋白酪氨酸磷酸酶基因、原癌基因蛋白mRNA显著上调,胶原V型α-2基因显著下调。结论80K-L蛋白基因、蛋白酪氨酸磷酸酶基因、原癌基因蛋白、胶原V型α-2基因异常可能与食管癌发生、发展和转移相关。uPAR基因可能被利用在外周血诊断食管癌微转移具有重要意义。     

口服核糖核酸（RNA）制剂对肺癌术后恢复的临床观察

２０多例癌患者手术后服用核糖核酸（ＲＮＡ）制剂，经３年的临床跟踪观察证实；服用ＲＮＡ制剂病人的白细胞（ＷＢＣ０计数，血沉（ＥＳＲ），免疫球蛋白（ＩｇＣ、ＩｇＡ、ＩｇＭ），淋巴细胞亚群Ｔ４Ｔ８和超氧歧化酶（ＳＯＤ）诸基指标的稳定率为１００％。患者的１年生存率为１００％；２年生存率为９５％；３年生存率为７５％，而术后示服用ＲＮＡ制剂而采用化疗的２０例对照组的１年生存率为８０％；２年生存率为５０％；３年     

食管癌细胞中c-erbB-2与P-gP表达的相关性

目的　探讨食管癌细胞c erbB 2与多药耐药性相关性及其临床意义。方法　用免疫组化方法检测癌细胞c erbB 2和用流式细胞术检测了 4 6例食管癌手术标本中癌细胞P 糖蛋白 (P gp)表达水平 ,并进行相关性分析。 结果　食管癌中c erbB 2表达阳性 12 / 4 6例 (2 6 1% ) ;P gp表达阳性 2 8/ 4 6例 (6 0 9% )。食管癌淋巴结转移情况与c erbB 2和P gp表达比较发现 ,在c erbB 2阳性时淋巴结有转移 (31 0 9%± 5 33% )与无转移 (8 0 4 %± 3 0 3% )组的P gp表达比较差异有显著性(P =0 0 0 73) ,而在c erbB 2阴性时淋巴结转移情况与P gp表达无相关性。食管癌临床分期与c erbB 2和P gp表达比较发现 ,在c erbB 2阳性时 ,Ⅲ～Ⅳ期 (33 6 8%± 5 5 1% )与Ⅱ期 (9 30 %± 2 78% )组P gp表达比较 ,差异有显著性 (P =0 0 0 2 7) ,而在c erbB 2阴性时临床分期与P gp表达无相关性。食管癌肿瘤大小、肿瘤分化程度与c erbB 2和P gp表达均无相关性。结论　在c erbB 2表达阳性时食管癌中有淋巴结转移、临床Ⅲ～Ⅳ期患者与P gp表达升高有相关性 ,提示双阳性时肿瘤患者预后较差。但在c erbB 2表达阴性时食管癌有淋巴结转移、临床分期与P gp表达无相关性     

血清类粘蛋白的极譜分析

血清类粘蛋白是一种酸性糖蛋白,属于α_1-球蛋白组分,含糖量甚高,約为40％。类粘蛋白只能沉淀于磷鎢酸和酒精中,不被三氯醋酸、磺基水杨酸、过氯酸等所沉淀,加热不凝固。血清中类粘蛋白含量很低,仅占血清总蛋白的1％左右,它在肿瘤、肝疾病等許多病理状态下可发生明显的改变。1939年Brdi(?)ka首先应用极譜法測定血清磺基水杨酸滤液于鈷—銨緩冲液中的蛋白催化波,发现癌肿病人血清滤液的催化波显著升高,但并非为特異性变化,在发热、結核病患者等的血清滤液,其极譜活性亦有类似的变化。以后Hasselbach     

Prognostic Value of P-gp and p27 in Patients with Esophageal Squamous Cell Carcinoma

Objective： To evaluate the prognostic value of P-gp and p27 expression in patients with esophageal squamous cell carcinoma （ESC）. Methods： The expressions of P-gp and p27 were detected by immunohistochemistry in 104 cases of ESC, and the clinicopathological characteristics were analyzed as well. Results： The positive rate of P-gp expression in 104 cases of ESCs was 32.7%. The positive rate of P-gp expression in the group that survived over 3 years （17.5%） was significantly lower than that in the group died within 3 years （53.3%） （x^2=14.227, P〈0.001）. The positive rate of p27 expression in 104 cases of ESCs was 67.3%. The positive rate of p27 expression in the group that survived over 3 years （75.8%） was significantly higher than that in the group died within 3 years （56.5%） （x^2=4.361, P〈0.05）. The patients with poorer differentiation whole wall invasion, lymph node metastasis and more advanced TNM stage had a shorter survival than did those with better differentiation, more superficial invasion, no lymph node involvement and earlier TNM stage; and it was statistically significant （P〈0.05）. However, tumor size, macropathologic type, age and gender had no prognostic impact on ESC patients （P〉0.05）. Conclusion： P-gp and p27 expression levels had a clinical prognostic significance in ESC. It could provide a reference basis for selecting the chemotherapy projection. The tumor differentiation degree, depth of invasion, lymph node involvement and TNM stages all were correlated to ESC patients＇ survival.